Sarah Wordsworth, PhD
University of Oxford
H-index: 44
Europe-United Kingdom
Top articles of Sarah Wordsworth, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Paving the path for implementation of clinical genomic sequencing globally-Are we ready? | Health Affairs Scholar | Deborah A Marshall Nicolle Hua James Buchanan Kurt D Christensen Geert WJ Frederix | 2024/4/29 |
Population screening requires robust evidence—genomics is no exception | Clare Turnbull Helen V Firth Andrew OM Wilkie William Newman F Lucy Raymond | 2024/2/10 | |
Protocol: Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness—a protocol for a randomised controlled … | BMJ Open | Mae Hazell Barnaby Reeves Chris A Rogers Katie Pike Lucy Culliford | 2024 |
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness—a protocol for a randomised controlled trial … | BMJ open | Mae Hazell Barnaby Reeves Chris A Rogers Katie Pike Lucy Culliford | 2024/1/1 |
The ADAPTT study | Jessica Harris Koen B Pouwels Thomas Johnson Jonathan Sterne Christalla Pithara | 2023/5 | |
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries | Personalized Medicine | László Szilberhorn Tamás Zelei Heleen Vellekoop Simone Huygens Matthijs Versteegh | 2023/7 |
Roux-en-Y gastric bypass, gastric banding or sleeve gastrectomy for severe obesity: baseline data from the By-Band-Sleeve RCT | Obesity | Graziella G Mazza Jane Blazeby Chris A Rogers Barnaby C Reeves Eleanor A Gidman | 2023/1/1 |
Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib | Value in Health | Simone Huygens Heleen Vellekoop Matthijs Versteegh Irene Santi László Szilberhorn | 2023/2/1 |
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19· 67 million people and evaluation of model … | The Lancet Respiratory Medicine | Weiqi Liao Carol AC Coupland Judith Burchardt David R Baldwin Fergus Gleeson | 2023/8/1 |
Qualitative study with patients | Jessica Harris Koen B Pouwels Thomas Johnson Jonathan Sterne Christalla Pithara | 2023/5 | |
Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK | Personalized Medicine | Rositsa Koleva-Kolarova Heleen Vellekoop Simone Huygens Matthijs Versteegh Maureen Rutten-van Mölken | 2023/7 |
Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial | The Lancet Infectious Diseases | Martin J Llewelyn Eric P Budgell Magda Laskawiec-Szkonter Elizabeth LA Cross Rebecca Alexander | 2023/2/1 |
Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three … | Personalized Medicine | Heleen Vellekoop Simone Huygens Matthijs Versteegh László Szilberhorn Tamás Zelei | 2023/7 |
Confounders study | Jessica Harris Koen B Pouwels Thomas Johnson Jonathan Sterne Christalla Pithara | 2023/5 | |
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation | Rositsa Koleva-Kolarova László Szilberhorn Tamás Zelei Heleen Vellekoop Balázs Nagy | 2023/7/1 | |
HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead | Maureen Rutten-van Mölken Matthijs Versteegh Balázs Nagy Sarah Wordsworth | 2023/7 | |
Evaluating the Impact of Genome Sequencing on Healthcare Resource Use: Evidence from Cancer Patients | Academy of Management Proceedings | Sandra Barbosu Sarah Wordsworth John Buckell James Buchanan | 2023 |
Roux‐en‐Y gastric bypass, gastric banding, or sleeve gastrectomy for severe obesity: Baseline data from the By‐Band‐Sleeve randomized controlled trial | Obesity | ‐Band‐Sleeve Collaborative Group Richard Welbourn Trial Management Group Robert C Andrews John Bessent | 2023/5 |
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems | Personalized Medicine | Rositsa Koleva-Kolarova Heleen Vellekoop Simone Huygens Matthijs Versteegh Maureen Rutten-van Mölken | 2023/7 |
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies | Personalized Medicine | Balázs Nagy Tamás Zelei Heleen Vellekoop Simone Huygens Matthijs Versteegh | 2023/7 |
Co-Authors
